Research graph
References from Hippocampal mechanisms and neural circuitry of negative symptoms in schizophrenia. Local targets link to admitted publications; unresolved targets remain external evidence.
Pomgulated methionil (LY2140023) in schizophrenia patients: a systematic review and meta-analysis
10.1186/s12888-025-07199-z · 2025 · External reference
Pomaglumetad Methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison
10.1155/2014/758212 · 2014 · External reference
What does the amygdala contribute to social cognition?
10.1111/j.1749-6632.2010.05445.x · 2010 · External reference
Updated meta-analyses reveal thalamus volume reduction in patients with first-episode and chronic schizophrenia
10.1016/j.schres.2010.07.007 · 2010 · External reference
Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia?
10.1016/j.pneurobio.2005.11.005 · 2005 · External reference
Therapeutic effect of evenamide, a glutamate inhibitor, in patients with treatment-resistant schizophrenia (TRS): final, 1-year results from a phase 2, open-label, rater-blinded, randomized, international clinical trial
10.1093/ijnp/pyae061 · 2024 · External reference
10.1016/j.neuropharm.2024.110275
10.1016/j.neuropharm.2024.110275 · 2025 · External reference
Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials
10.1177/20451253251414529 · 2026 · External reference
Amygdala connectivity differs among chronic, early course, and individuals at risk for developing schizophrenia
10.1093/schbul/sbt165 · 2014 · External reference
Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions
10.1093/schbul/sbq068 · 2010 · External reference
Role of the prefrontal cortex in altered hippocampal-accumbens synaptic plasticity in a developmental animal model of schizophrenia
2014 · External reference
N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial
10.1016/j.biopsych.2008.03.004 · 2008 · External reference
Human striatal response to reward anticipation linked to hippocampal glutamate levels
10.1093/ijnp/pyy011 · 2018 · External reference
Aberrant striatal coupling with default mode and central executive network relates to self-reported avolition and anhedonia in schizophrenia
10.1016/j.jpsychires.2020.10.047 · 2022 · External reference
Perineuronal nets protect fast-spiking interneurons against oxidative stress
10.1073/pnas.1300454110 · 2013 · External reference
Frontal-striatum dysfunction during reward processing: relationships to amotivation in schizophrenia
10.1037/abn0000137 · 2016 · External reference
N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis
10.1093/schbul/sbx093 · 2018 · External reference
Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment
10.2147/ndt.s225643 · 2020 · External reference
Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials
10.1038/s41380-026-03543-1 · 2026 · External reference
Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients
10.1016/j.schres.2024.09.030 · 2024 · External reference
The thalamic midline nucleus reuniens: potential relevance for schizophrenia and epilepsy
10.1016/j.neubiorev.2020.09.033 · 2020 · External reference
Modulation of extrasynaptic GABAA alpha 5 receptors in the ventral hippocampus normalizes physiological and behavioral deficits in a circuit specific manner
10.1038/s41467-019-10800-1 · 2019 · External reference
Amygdala hyperactivity in MAM model of schizophrenia is normalized by peripubertal diazepam administration
10.1038/npp.2016.42 · 2016 · External reference
Beyond dopamine: novel strategies for schizophrenia treatment
10.1002/med.22042 · 2024 · External reference
Limbic hyperactivity in response to emotionally neutral stimuli in schizophrenia: a neuroimaging Meta-analysis of the hypervigilant mind
10.1176/appi.ajp.2019.19030247 · 2019 · External reference
Left amygdala alterations mediate the effects of negative symptoms on social dysfunction in schizophrenia
10.1038/s41537-025-00655-5 · 2025 · External reference
Impact of primary negative symptoms on functional outcomes in schizophrenia
10.1016/j.eurpsy.2014.01.007 · 2014 · External reference
GABAA -receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits
10.1002/cne.903590111 · 1995 · External reference
The pathophysiology of negative symptoms of schizophrenia: main hypotheses and open challenges
10.1192/bjp.2023.63 · 2023 · External reference
Negative symptoms of schizophrenia: new developments and unanswered research questions
10.1016/s2215-0366(18)30050-6 · 2018 · External reference
Reduced resting state functional connectivity in the hippocampus-midbrain-striatum network of schizophrenia patients
10.1016/j.jpsychires.2021.03.041 · 2021 · External reference
Altered age-related trajectories of amygdala-prefrontal circuitry in adolescents at clinical high risk for psychosis: a preliminary study
10.1016/j.schres.2011.10.005 · 2012 · External reference
The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia
10.2174/1381612819666131216114612 · 2014 · External reference
Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model
10.1017/s146114571400056x · 2014 · External reference
Gender differences in clinical and psychosocial features among persons with schizophrenia: a mini review
2021 · External reference
Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention
10.3390/ijms22094467 · 2021 · External reference
Adolescence as a period of vulnerability and intervention in schizophrenia: insights from the MAM model
10.1016/j.neubiorev.2016.05.030 · 2016 · External reference
The ventral/anterior hippocampus as a central hub for stress-related dopaminergic circuit dysfunction in psychiatric disorders
10.1038/s41380-026-03513-7 · 2026 · External reference
Antipsychotic drug action, novel treatment targets, and the failure of current clinical trial designs in evaluating new target molecules
10.1016/j.biopsych.2026.06.010 · 2026 · External reference
Neuroanatomical and symptomatic sex differences in individuals at clinical high risk for psychosis
2017 · External reference
Deconstructing negative symptoms in individuals at clinical high-risk for psychosis: evidence for volitional and diminished emotionality subgroups that predict clinical presentation and functional outcome
10.1093/schbul/sbaa084 · 2021 · External reference
Parvalbumin and anxiety across development in female offspring of the MAM neurodevelopmental model of schizophrenia
10.1016/j.jpsychires.2026.07.002 · 2026 · External reference
GABAergic mechanisms of hippocampal hyperactivity in schizophrenia
10.1016/j.schres.2014.09.041 · 2015 · External reference
Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat
10.1007/s00429-007-0150-4 · 2007 · External reference
Fast-spiking, parvalbumin+ GABAergic interneurons: from cellular design to microcircuit function
10.1126/science.1255263 · 2014 · External reference
Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia
10.1176/appi.ajp.160.1.13 · 2003 · External reference
Long-term safety and efficacy of xanomeline and trospium chloride in schizophrenia: a 52-week open-label extension trial
10.1176/appi.ajp.20241186 · 2026 · External reference
Secondary negative symptoms — a review of mechanisms, assessment and treatment
10.1016/j.schres.2016.05.003 · 2017 · External reference
Neural activation during cognitive effort-based decision making: associations with avolition in veterans with schizophrenia and bipolar disorder
2026 · External reference
Schizophrenia
10.1038/s41572-025-00667-6 · 2025 · External reference
Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
10.1016/j.tins.2011.10.004 · 2012 · External reference
Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: still promising or a dead end?
10.1016/j.pnpbp.2015.02.012 · 2015 · External reference
Why sex differences in schizophrenia?
2016 · External reference
Affective flattening in patients with schizophrenia: differential association with amygdala response to threat-related facial expression under automatic and controlled processing conditions
10.4306/pi.2016.13.1.102 · 2016 · External reference
Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia
10.1523/jneurosci.2847-07.2007 · 2007 · External reference
A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia
10.1523/jneurosci.5419-08.2009 · 2009 · External reference
The current conceptualization of negative symptoms in schizophrenia
10.1002/wps.20385 · 2017 · External reference
Schizophrenia, dopamine and the striatum: from biology to symptoms
10.1016/j.tins.2018.12.004 · 2019 · External reference
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
10.1002/wps.20693 · 2020 · External reference
Afferent projections to nucleus reuniens of the thalamus
10.1002/cne.20342 · 2004 · External reference
Acetylcholine muscarinic receptors in ventral hippocampus modulate stress-induced anxiety-like behaviors in mice
10.3389/fnmol.2020.598811 · 2020 · External reference
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials
10.1093/ijnp/pyaf015 · 2025 · External reference
Translating the MAM model of psychosis to humans
10.1016/j.tins.2014.12.005 · 2015 · External reference
Sex differences in schizophrenia: symptomatology, treatment efficacy and adverse effects
2025 · External reference
A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia
10.1016/j.biopsych.2006.01.003 · 2006 · External reference
Primary and secondary negative symptoms in schizophrenia
2022 · External reference
Altered amygdala connectivity within the social brain in schizophrenia
10.1093/schbul/sbt086 · 2014 · External reference
Thalamic hyperperfusion in early schizophrenia: associations with cognitive deficits and negative symptoms
10.1016/j.schres.2025.08.014 · 2025 · External reference
The thalamic reticular nucleus: structure, function and concept
10.1016/j.brainresrev.2004.04.008 · 2004 · External reference
Reciprocal connections between the amygdala and the hippocampal formation, perirhinal cortex, and postrhinal cortex in rat: a review
10.1111/j.1749-6632.2000.tb06738.x · 2000 · External reference
Medial prefrontal cortex pathology in schizophrenia as revealed by convergent findings from multimodal imaging
10.1038/mp.2009.146 · 2010 · External reference
A functional neuroimaging meta-analysis of self-related processing in schizophrenia
10.3389/fneur.2019.00990 · 2019 · External reference
Abnormalities in behavior relevant to schizophrenia in embryonic day 17 MAM-exposed rodent models: a systematic review and meta-analysis
10.1016/j.pbb.2024.173888 · 2024 · External reference
Hippocampal-cortical structural connectivity disruptions in schizophrenia: an integrated perspective from hippocampal shape, cortical thickness, and integrity of white matter bundles
10.1016/j.neuroimage.2010.05.046 · 2010 · External reference
Negative symptoms in schizophrenia show association with amygdala volumes and neural activation during affective processing
10.1017/neu.2015.11 · 2015 · External reference
Hippocampus and amygdala in schizophrenia: assessment of the relationship of neuroanatomy to psychopathology
10.1016/s0925-4927(01)00120-2 · 2001 · External reference
Effects of estrogen on brain development and neuroprotection—implications for negative symptoms in schizophrenia
10.1016/s0306-4530(02)00126-9 · 2003 · External reference
Menopausal hormone therapy for women with schizophrenia: what’s stopping us?
10.1176/appi.ajp.20240770 · 2024 · External reference
Elevated fear states facilitate ventral hippocampal engagement of basolateral amygdala neuronal activity
10.3389/fnbeh.2024.1347525 · 2024 · External reference
Brain-based sex differences in schizophrenia: a systematic review of fMRI studies
10.1002/hbm.26664 · 2024 · External reference
Alterations in hippocampal connectivity across the psychosis dimension
10.1016/j.pscychresns.2015.06.004 · 2015 · External reference
The distribution of muscarinic M1 receptors in the human hippocampus
10.1016/j.jchemneu.2016.07.006 · 2016 · External reference
Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders
10.1001/archgenpsychiatry.2009.115 · 2009 · External reference
Neural correlates of schizophrenia negative symptoms: distinct subtypes impact dissociable brain circuits
10.1159/000440979 · 2015 · External reference
Evenamide hydrochloride. Voltage-gated sodium channel blocker, treatment of schizophrenia
10.1358/dof.2019.44.9.2921069 · 2019 · External reference
Women with schizophrenia-spectrum disorders after menopause: a vulnerable group for relapse
10.1093/schbul/sbac139 · 2023 · External reference
The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus
10.1038/s41386-020-0764-2 · 2020 · External reference
The thalamic reticular nucleus in schizophrenia and bipolar disorder: role of parvalbumin-expressing neuron networks and oxidative stress
10.1038/mp.2017.230 · 2018 · External reference
Avolition in schizophrenia is associated with reduced willingness to expend effort for reward on a progressive ratio task
10.1016/j.schres.2015.12.006 · 2016 · External reference
Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia
10.1176/appi.ajp.2013.13070981 · 2014 · External reference
Age- and sex-dependent effects of stressors on activity of the nucleus reuniens of the thalamus
10.1016/j.schres.2025.09.018 · 2025 · External reference
Stress impacts corticoamygdalar connectivity in an age-dependent manner
10.1038/s41386-020-00886-3 · 2021 · External reference
Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model
10.1038/s41386-025-02188-y · 2025 · External reference
Novel positive allosteric modulators of alpha 5 subunit-containing GABAA receptors (α5-GABAARs) reverse the hyperdopaminergic state in a neurodevelopmental model of schizophrenia
10.1016/j.schres.2026.02.010 · 2026 · External reference
Efferent projections of reuniens and rhomboid nuclei of the thalamus in the rat
10.1002/cne.21135 · 2006 · External reference
Nucleus Reuniens: circuitry, function, and dysfunction
2022 · External reference
Limbic links to paranoia: increased resting-state functional connectivity between amygdala, hippocampus and orbitofrontal cortex in schizophrenia patients with paranoia
10.1007/s00406-021-01337-w · 2022 · External reference
Hippocampal temporal-parietal junction interaction in the production of psychotic symptoms: a framework for understanding the schizophrenic syndrome
10.3389/fnhum.2012.00180 · 2012 · External reference
Optogenetic induction of the schizophrenia-related endophenotype of ventral hippocampal hyperactivity causes rodent correlates of positive and cognitive symptoms
10.1038/s41598-018-31163-5 · 2018 · External reference
Neural substrates of reward anticipation and outcome in schizophrenia: a meta-analysis of fMRI findings in the monetary incentive delay task
10.1038/s41398-022-02201-8 · 2022 · External reference
Abnormalities of the amygdala in schizophrenia: a real world study
10.1186/s12888-023-05031-0 · 2023 · External reference
Sex- and exposure age-dependent effects of adolescent stress on ventral tegmental area dopamine system and its afferent regulators
2022 · External reference
Thalamic reticular nucleus impairments and abnormal prefrontal control of dopamine system in a developmental model of schizophrenia: prevention by N-acetylcysteine
10.1038/s41380-021-01198-8 · 2021 · External reference
Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders
10.1001/archgenpsychiatry.2009.115 · ExternalCitation · doi-reference
Afferent projections to nucleus reuniens of the thalamus
10.1002/cne.20342 · ExternalCitation · doi-reference
Efferent projections of reuniens and rhomboid nuclei of the thalamus in the rat
10.1002/cne.21135 · ExternalCitation · doi-reference
GABAA -receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits
10.1002/cne.903590111 · ExternalCitation · doi-reference
Brain-based sex differences in schizophrenia: a systematic review of fMRI studies
10.1002/hbm.26664 · ExternalCitation · doi-reference
Beyond dopamine: novel strategies for schizophrenia treatment
10.1002/med.22042 · ExternalCitation · doi-reference
The current conceptualization of negative symptoms in schizophrenia
10.1002/wps.20385 · ExternalCitation · doi-reference
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
10.1002/wps.20693 · ExternalCitation · doi-reference
Limbic links to paranoia: increased resting-state functional connectivity between amygdala, hippocampus and orbitofrontal cortex in schizophrenia patients with paranoia
10.1007/s00406-021-01337-w · ExternalCitation · doi-reference
Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat
10.1007/s00429-007-0150-4 · ExternalCitation · doi-reference
A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia
10.1016/j.biopsych.2006.01.003 · ExternalCitation · doi-reference
N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial
10.1016/j.biopsych.2008.03.004 · ExternalCitation · doi-reference
Antipsychotic drug action, novel treatment targets, and the failure of current clinical trial designs in evaluating new target molecules
10.1016/j.biopsych.2026.06.010 · ExternalCitation · doi-reference
The thalamic reticular nucleus: structure, function and concept
10.1016/j.brainresrev.2004.04.008 · ExternalCitation · doi-reference
Impact of primary negative symptoms on functional outcomes in schizophrenia
10.1016/j.eurpsy.2014.01.007 · ExternalCitation · doi-reference
The distribution of muscarinic M1 receptors in the human hippocampus
10.1016/j.jchemneu.2016.07.006 · ExternalCitation · doi-reference
Aberrant striatal coupling with default mode and central executive network relates to self-reported avolition and anhedonia in schizophrenia
10.1016/j.jpsychires.2020.10.047 · ExternalCitation · doi-reference
Reduced resting state functional connectivity in the hippocampus-midbrain-striatum network of schizophrenia patients
10.1016/j.jpsychires.2021.03.041 · ExternalCitation · doi-reference
Parvalbumin and anxiety across development in female offspring of the MAM neurodevelopmental model of schizophrenia
10.1016/j.jpsychires.2026.07.002 · ExternalCitation · doi-reference
Adolescence as a period of vulnerability and intervention in schizophrenia: insights from the MAM model
10.1016/j.neubiorev.2016.05.030 · ExternalCitation · doi-reference
The thalamic midline nucleus reuniens: potential relevance for schizophrenia and epilepsy
10.1016/j.neubiorev.2020.09.033 · ExternalCitation · doi-reference
Hippocampal-cortical structural connectivity disruptions in schizophrenia: an integrated perspective from hippocampal shape, cortical thickness, and integrity of white matter bundles
10.1016/j.neuroimage.2010.05.046 · ExternalCitation · doi-reference
10.1016/j.neuropharm.2024.110275
10.1016/j.neuropharm.2024.110275 · ExternalCitation · doi-reference
Abnormalities in behavior relevant to schizophrenia in embryonic day 17 MAM-exposed rodent models: a systematic review and meta-analysis
10.1016/j.pbb.2024.173888 · ExternalCitation · doi-reference
Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia?
10.1016/j.pneurobio.2005.11.005 · ExternalCitation · doi-reference
Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: still promising or a dead end?
10.1016/j.pnpbp.2015.02.012 · ExternalCitation · doi-reference
Alterations in hippocampal connectivity across the psychosis dimension
10.1016/j.pscychresns.2015.06.004 · ExternalCitation · doi-reference
Updated meta-analyses reveal thalamus volume reduction in patients with first-episode and chronic schizophrenia
10.1016/j.schres.2010.07.007 · ExternalCitation · doi-reference
Altered age-related trajectories of amygdala-prefrontal circuitry in adolescents at clinical high risk for psychosis: a preliminary study
10.1016/j.schres.2011.10.005 · ExternalCitation · doi-reference
GABAergic mechanisms of hippocampal hyperactivity in schizophrenia
10.1016/j.schres.2014.09.041 · ExternalCitation · doi-reference
Avolition in schizophrenia is associated with reduced willingness to expend effort for reward on a progressive ratio task
10.1016/j.schres.2015.12.006 · ExternalCitation · doi-reference
Secondary negative symptoms — a review of mechanisms, assessment and treatment
10.1016/j.schres.2016.05.003 · ExternalCitation · doi-reference
Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients
10.1016/j.schres.2024.09.030 · ExternalCitation · doi-reference
Thalamic hyperperfusion in early schizophrenia: associations with cognitive deficits and negative symptoms
10.1016/j.schres.2025.08.014 · ExternalCitation · doi-reference
Age- and sex-dependent effects of stressors on activity of the nucleus reuniens of the thalamus
10.1016/j.schres.2025.09.018 · ExternalCitation · doi-reference
Novel positive allosteric modulators of alpha 5 subunit-containing GABAA receptors (α5-GABAARs) reverse the hyperdopaminergic state in a neurodevelopmental model of schizophrenia
10.1016/j.schres.2026.02.010 · ExternalCitation · doi-reference
Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
10.1016/j.tins.2011.10.004 · ExternalCitation · doi-reference
Translating the MAM model of psychosis to humans
10.1016/j.tins.2014.12.005 · ExternalCitation · doi-reference
Schizophrenia, dopamine and the striatum: from biology to symptoms
10.1016/j.tins.2018.12.004 · ExternalCitation · doi-reference
Effects of estrogen on brain development and neuroprotection—implications for negative symptoms in schizophrenia
10.1016/s0306-4530(02)00126-9 · ExternalCitation · doi-reference
Hippocampus and amygdala in schizophrenia: assessment of the relationship of neuroanatomy to psychopathology
10.1016/s0925-4927(01)00120-2 · ExternalCitation · doi-reference
Negative symptoms of schizophrenia: new developments and unanswered research questions
10.1016/s2215-0366(18)30050-6 · ExternalCitation · doi-reference
Negative symptoms in schizophrenia show association with amygdala volumes and neural activation during affective processing
10.1017/neu.2015.11 · ExternalCitation · doi-reference
Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model
10.1017/s146114571400056x · ExternalCitation · doi-reference
Frontal-striatum dysfunction during reward processing: relationships to amotivation in schizophrenia
10.1037/abn0000137 · ExternalCitation · doi-reference
Medial prefrontal cortex pathology in schizophrenia as revealed by convergent findings from multimodal imaging
10.1038/mp.2009.146 · ExternalCitation · doi-reference
The thalamic reticular nucleus in schizophrenia and bipolar disorder: role of parvalbumin-expressing neuron networks and oxidative stress
10.1038/mp.2017.230 · ExternalCitation · doi-reference
Amygdala hyperactivity in MAM model of schizophrenia is normalized by peripubertal diazepam administration
10.1038/npp.2016.42 · ExternalCitation · doi-reference
Thalamic reticular nucleus impairments and abnormal prefrontal control of dopamine system in a developmental model of schizophrenia: prevention by N-acetylcysteine
10.1038/s41380-021-01198-8 · ExternalCitation · doi-reference
The ventral/anterior hippocampus as a central hub for stress-related dopaminergic circuit dysfunction in psychiatric disorders
10.1038/s41380-026-03513-7 · ExternalCitation · doi-reference
Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials
10.1038/s41380-026-03543-1 · ExternalCitation · doi-reference
Stress impacts corticoamygdalar connectivity in an age-dependent manner
10.1038/s41386-020-00886-3 · ExternalCitation · doi-reference
The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus
10.1038/s41386-020-0764-2 · ExternalCitation · doi-reference
Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model
10.1038/s41386-025-02188-y · ExternalCitation · doi-reference
Neural substrates of reward anticipation and outcome in schizophrenia: a meta-analysis of fMRI findings in the monetary incentive delay task
10.1038/s41398-022-02201-8 · ExternalCitation · doi-reference
Modulation of extrasynaptic GABAA alpha 5 receptors in the ventral hippocampus normalizes physiological and behavioral deficits in a circuit specific manner
10.1038/s41467-019-10800-1 · ExternalCitation · doi-reference
Left amygdala alterations mediate the effects of negative symptoms on social dysfunction in schizophrenia
10.1038/s41537-025-00655-5 · ExternalCitation · doi-reference
Schizophrenia
10.1038/s41572-025-00667-6 · ExternalCitation · doi-reference
Optogenetic induction of the schizophrenia-related endophenotype of ventral hippocampal hyperactivity causes rodent correlates of positive and cognitive symptoms
10.1038/s41598-018-31163-5 · ExternalCitation · doi-reference
Perineuronal nets protect fast-spiking interneurons against oxidative stress
10.1073/pnas.1300454110 · ExternalCitation · doi-reference
Therapeutic effect of evenamide, a glutamate inhibitor, in patients with treatment-resistant schizophrenia (TRS): final, 1-year results from a phase 2, open-label, rater-blinded, randomized, international clinical trial
10.1093/ijnp/pyae061 · ExternalCitation · doi-reference
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials
10.1093/ijnp/pyaf015 · ExternalCitation · doi-reference
Human striatal response to reward anticipation linked to hippocampal glutamate levels
10.1093/ijnp/pyy011 · ExternalCitation · doi-reference
Deconstructing negative symptoms in individuals at clinical high-risk for psychosis: evidence for volitional and diminished emotionality subgroups that predict clinical presentation and functional outcome
10.1093/schbul/sbaa084 · ExternalCitation · doi-reference
Women with schizophrenia-spectrum disorders after menopause: a vulnerable group for relapse
10.1093/schbul/sbac139 · ExternalCitation · doi-reference
Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions
10.1093/schbul/sbq068 · ExternalCitation · doi-reference
Altered amygdala connectivity within the social brain in schizophrenia
10.1093/schbul/sbt086 · ExternalCitation · doi-reference
Amygdala connectivity differs among chronic, early course, and individuals at risk for developing schizophrenia
10.1093/schbul/sbt165 · ExternalCitation · doi-reference
N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis
10.1093/schbul/sbx093 · ExternalCitation · doi-reference
Reciprocal connections between the amygdala and the hippocampal formation, perirhinal cortex, and postrhinal cortex in rat: a review
10.1111/j.1749-6632.2000.tb06738.x · ExternalCitation · doi-reference
What does the amygdala contribute to social cognition?
10.1111/j.1749-6632.2010.05445.x · ExternalCitation · doi-reference
Fast-spiking, parvalbumin+ GABAergic interneurons: from cellular design to microcircuit function
10.1126/science.1255263 · ExternalCitation · doi-reference
Pomaglumetad Methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison
10.1155/2014/758212 · ExternalCitation · doi-reference
Neural correlates of schizophrenia negative symptoms: distinct subtypes impact dissociable brain circuits
10.1159/000440979 · ExternalCitation · doi-reference
Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia
10.1176/appi.ajp.160.1.13 · ExternalCitation · doi-reference
Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia
10.1176/appi.ajp.2013.13070981 · ExternalCitation · doi-reference
Limbic hyperactivity in response to emotionally neutral stimuli in schizophrenia: a neuroimaging Meta-analysis of the hypervigilant mind
10.1176/appi.ajp.2019.19030247 · ExternalCitation · doi-reference
Menopausal hormone therapy for women with schizophrenia: what’s stopping us?
10.1176/appi.ajp.20240770 · ExternalCitation · doi-reference
Long-term safety and efficacy of xanomeline and trospium chloride in schizophrenia: a 52-week open-label extension trial
10.1176/appi.ajp.20241186 · ExternalCitation · doi-reference
Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials
10.1177/20451253251414529 · ExternalCitation · doi-reference
Abnormalities of the amygdala in schizophrenia: a real world study
10.1186/s12888-023-05031-0 · ExternalCitation · doi-reference
Pomgulated methionil (LY2140023) in schizophrenia patients: a systematic review and meta-analysis
10.1186/s12888-025-07199-z · ExternalCitation · doi-reference
The pathophysiology of negative symptoms of schizophrenia: main hypotheses and open challenges
10.1192/bjp.2023.63 · ExternalCitation · doi-reference
Evenamide hydrochloride. Voltage-gated sodium channel blocker, treatment of schizophrenia
10.1358/dof.2019.44.9.2921069 · ExternalCitation · doi-reference
Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia
10.1523/jneurosci.2847-07.2007 · ExternalCitation · doi-reference
A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia
10.1523/jneurosci.5419-08.2009 · ExternalCitation · doi-reference
Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment
10.2147/ndt.s225643 · ExternalCitation · doi-reference
The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia
10.2174/1381612819666131216114612 · ExternalCitation · doi-reference
Elevated fear states facilitate ventral hippocampal engagement of basolateral amygdala neuronal activity
10.3389/fnbeh.2024.1347525 · ExternalCitation · doi-reference
A functional neuroimaging meta-analysis of self-related processing in schizophrenia
10.3389/fneur.2019.00990 · ExternalCitation · doi-reference
Hippocampal temporal-parietal junction interaction in the production of psychotic symptoms: a framework for understanding the schizophrenic syndrome
10.3389/fnhum.2012.00180 · ExternalCitation · doi-reference
Acetylcholine muscarinic receptors in ventral hippocampus modulate stress-induced anxiety-like behaviors in mice
10.3389/fnmol.2020.598811 · ExternalCitation · doi-reference
Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention
10.3390/ijms22094467 · ExternalCitation · doi-reference
Affective flattening in patients with schizophrenia: differential association with amygdala response to threat-related facial expression under automatic and controlled processing conditions
10.4306/pi.2016.13.1.102 · ExternalCitation · doi-reference
